Go to Health Care Provider version
| Diagnosis | Lymphoma | Study Status | Open |
| Phase | II |
| Age | 16 Years to 65 Years | Randomisation | YES |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | All participants will receive the drug Rituximab (IV) and Cisplatin (IV)
Depending on which participant group you are assigned, you may also receive:
Drug: Gemcitabine (IV)
Drug: Dexamethasone (Oral)
Drug: Mesna (IV)
Drug: Cyclophosphamide (IV)
Drug: Etoposide (IV)
Drug: G-CSF (SC)
Drug: Selinexor (Oral) |
| Last Posted Update | 2024-08-21 |
| ClinicalTrials.gov # | NCT02436707 |
International Sponsor
Canadian Cancer Trials GroupPrincipal Investigators for Canadian Sites
CancerCare Manitoba - Dr. Pamela SkrabekCentres
Study Description
The purpose of this study is to find out what effects new combinations of treatment will help in treating a cancer called lymphoma. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.
Inclusion Criteria
- Participants must be between 16 to 65 years old to participate
- Participants must have one of the following diagnoses:
- Diffuse large cell lymphoma, B-cell (includes primary mediastinal B-cell lymphoma, T-cell rich B-cell lymphoma)
- Previous indolent lymphoma with transformation to diffuse large B-cell lymphoma at most recent relapse
- Unclassifiable B-cell lymphoma with indeterminate features between diffuse large B-cell lymphoma and Burkitt lymphoma
- Participants must have the presence of a protein called CD20
- Must meet all bloodwork requirements
- Participants who can bare children must have a negative pregnancy test prior to starting
- Participants must be willing to sign a consent form and agree to the study schedule
Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.
